Literature DB >> 11761337

Heparin-binding EGF-like growth factor decreases inducible nitric oxide synthase and nitric oxide production after intestinal ischemia/reperfusion injury.

G Xia1, M Lara-Marquez, M H Luquette, S Glenn, A Haque, G E Besner.   

Abstract

Heparin-binding epidermal growth factor-like growth factor (HB-EGF) has been shown to protect intestine from ischemia/reperfusion (I/R) injury in vivo and to down-regulate inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in intestinal epithelial cells in vitro. The present study was undertaken to investigate whether HB-EGF could modulate the iNOS/NO axis after total midgut I/R injury in rats. I/R injury induced a significant increase in iNOS gene expression (quantified by real-time RT-PCR) and protein production (detected by western blots), as well as elevation of serum NO levels (measured by chemiluminescence assay). Nitrotyrosine (NT) and iNOS production colocalized immunohistochemically, with positive staining found mainly in villous and crypt epithelial cells, as well as ganglion cells. Intraluminal administration of HB-EGF 45 min after the start of a 90-min ischemic interval significantly decreased I/R-induced iNOS gene expression and protein production, as well as serum NO levels. Immunohistochemically, HB-EGF administration led to elimination of iNOS and NT staining in crypt epithelial cells and ganglion cells, with only weak staining that remained in villous epithelial cells. Thus, HB-EGF protects the intestine from I/R injury, at least partially, through down-regulation of the iNOS/NO/NT pathway, a mechanism that is central to I/R injury in multiple organ systems.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11761337     DOI: 10.1089/15230860152665073

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  8 in total

1.  Heparin-binding EGF-like growth factor protects pericytes from injury.

Authors:  Xiaoyi Yu; Andrei Radulescu; Chun-Liang Chen; Iyore O James; Gail E Besner
Journal:  J Surg Res       Date:  2010-09-17       Impact factor: 2.192

2.  Heparin-binding epidermal growth factor-like growth factor and mesenchymal stem cells act synergistically to prevent experimental necrotizing enterocolitis.

Authors:  Jixin Yang; Daniel Watkins; Chun-Liang Chen; Bharath Bhushan; Yu Zhou; Gail E Besner
Journal:  J Am Coll Surg       Date:  2012-07-21       Impact factor: 6.113

3.  Heparin-binding EGF-like growth factor decreases inflammatory cytokine expression after intestinal ischemia/reperfusion injury.

Authors:  Dorothy V Rocourt; Veela B Mehta; Gail E Besner
Journal:  J Surg Res       Date:  2007-02-07       Impact factor: 2.192

4.  Heparin-binding EGF-like growth factor (HB-EGF) therapy for intestinal injury: Application and future prospects.

Authors:  Jixin Yang; Yanwei Su; Yu Zhou; Gail E Besner
Journal:  Pathophysiology       Date:  2013-12-15

5.  Diminished survival of human cytotrophoblast cells exposed to hypoxia/reoxygenation injury and associated reduction of heparin-binding epidermal growth factor-like growth factor.

Authors:  Richard E Leach; Brian A Kilburn; Anelia Petkova; Roberto Romero; D Randall Armant
Journal:  Am J Obstet Gynecol       Date:  2008-04       Impact factor: 8.661

6.  Heparin-binding EGF-like growth factor (HB-EGF) promotes cell migration and adhesion via focal adhesion kinase.

Authors:  Yanwei Su; Gail E Besner
Journal:  J Surg Res       Date:  2014-03-03       Impact factor: 2.192

7.  Role of nitric oxide and peroxynitrite anion in lung injury induced by intestinal ischemia-reperfusion in rats.

Authors:  Jun-Lin Zhou; Guo-Hua Jin; Yi-Ling Yi; Jun-Lan Zhang; Xin-Li Huang
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

8.  Time-dependent alterations in serum NO concentration after oral administration of L-arginine, L-NAME, and allopurinol in intestinal ischemia/reperfusion.

Authors:  Amalia E Yanni; Eleutherios Margaritis; Nikolaos Liarakos; Alkisti Pantopoulou; Maria Poulakou; Maria Kostakis; Despoina Perrea; Alkis Kostakis
Journal:  Vasc Health Risk Manag       Date:  2008
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.